相关人员
Nabil specialises in IP and regulatory advice for clients ranging from start-ups to global players, with a particular focus on the life sciences and other technology-rich sectors.
Nabil provides pragmatic, commercially-minded advice with a focus on intellectual property strategy and regulatory compliance. In addition to advice on the identification, protection, commercialisation and enforcement of IP rights, Nabil supports clients with commercial contracts, due diligence, and regulatory compliance.
Prior to training as a solicitor, Nabil worked in early phase pharmaceutical R&D for AstraZeneca and chaired the Physical Organic Chemistry Group of the Royal Society of Chemistry.
Since 2021 | Senior Associate, Taylor Wessing |
2020 - 2021 | Associate, Taylor Wessing |
2018 - 2020 | Associate, Eversheds Sutherland |
2016 - 2017 | Senior solicitor, Hempsons |
2014 - 2016 | In-house counsel, International Procurement and Logistics |
2012 - 2014 | Trainee, Kempner & Partners |
2005 - 2008 | Associate team leader, AstraZeneca |
2003 - 2005 | R&D chemist, Avecia |
2001 - 2003 | Post-Doctoral Research Fellow, University of Groningen |
2014 | Admitted as a solicitor |
2013 | LLM, BPP Law School |
2011 | LPC, BPP Law School |
2010 | GDL, BPP Law School |
2002 | PhD, Cambridge University |
1997 | BSc (Hons) Medicinal Chemistry, University of Leeds |
最新新闻和观点
Global pharma groups Eli Lilly and AbbVie withdraw from UK’s branded medicines voluntary scheme
作者 Nabil Asaad, PhD 以及 Lauren Mounteney
Using quantum computing in life sciences
Nabil Asaad looks at the potential for quantum computing to revolutionise life sciences.
2 / 4 观点
Advising IP Group on option exercise to accelerate development of first-in-class gene therapy for patients with cystic fibrosis
作者 Colin McCall 以及 Nabil Asaad, PhD
CJEU referral on violations of data protection law on the basis of competition law and on the interpretation of the concept of health data
作者 Dr. Daniel Tietjen 以及 Dr. David Klein, LL.M. (Univ. of Washington), CIPP/E